Liraglutide could reduce monthly migraine days Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at the annual European Academy of Neurology (EAN) Congress 25
While many individuals experience positive results, GLP-1 receptor agonists are not ideal for those with certain medical conditions, such as pancreatitis, thyroid issues, or a personal/family history of medullary thyroid carcinoma
2016;99(Pt A):2851
Gastroenterology 86(6):15921610 Moake MM, Presley BC, Hill JG et al (2022) Point-of-care ultrasound to assess gastric content in pediatric emergency department procedural sedation patients
This specially designed drip contains up to 3 specialized medications to help you overcome and aid in your fast recovery
Modification of apoB lipoproteins via oxidation and glycation enhances their uptake through a number of receptors not down-regulated by cholesterol including CD36, scavenger receptor A, and lectin-like receptor family (see details below) (Figure 2) (46,47)